Overview

Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy

Status:
Completed

Trial end date:
2019-02-13

Target enrollment:

Participant gender:

Summary

The purpose of this research study is to learn whether patients whose disease grows after being treated with nivolumab or pembrolizumab respond to ipilimumab (Yervoy®) alone or in combination with nivolumab (Opdivo®).

Phase:

Phase 2

Details

Lead Sponsor:

Memorial Sloan Kettering Cancer Center
Parker Institute for Cancer Immunotherapy

Collaborators:

Bristol-Myers Squibb
Parker Institute for Cancer Immunotherapy

Treatments:

Antibodies, Monoclonal
Ipilimumab
Nivolumab